Focal radiotherapy

RADIATION3 trials

Sponsors

Neuro-Oncology Working Group of the German Cancer Society, British Columbia Cancer Agency, University of Miami

Conditions

Anaplastic AstrocytomaFallopian Tube CancerHigh Grade GliomaOligoastrocytomaOligodendrogliomaOvarian CancerPrimary Peritoneal Carcinoma

Phase 1

PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers.

British Columbia Cancer AgencyFallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Carcinoma

Start: 2018-04-01End: 2020-12-16Target: 22Updated: 2018-07-11

STARLITE for Unresectable High-Grade Gliomas

RecruitingNCT06428045

University of MiamiHigh Grade Glioma

Start: 2025-04-15End: 2030-04-30Target: 24Updated: 2026-06-25

Phase 3

Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide

CompletedNCT00717210

Neuro-Oncology Working Group of the German Cancer SocietyAnaplastic Astrocytoma, Oligoastrocytoma, Oligodendroglioma

Start: 1999-06-30End: 2008-03-31Updated: 2008-07-17

Related Papers

Synergistic Treatment with Antiretrovirals and Laser Interstitial Thermal ThErapy (STARLITE) for unresectable glioblastoma: A phase 1 study protocol

PLoS ONE2025-08-28

STARLITE SPIRIT CHECKLIST.

OPAL (Open@LaTrobe) (La Trobe University)2025-08-28

Phase I (safety assessment) of durvalumab (MEDI4736) with focal sensitizing radiotherapy in platinum resistant ovarian, primary peritoneal or fallopian tube epithelial carcinoma.

Journal of Clinical Oncology2019-05-201 citations

Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide

Neuro-Oncology2016-07-01225 citations

Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide.

Journal of Clinical Oncology2015-05-2045 citations